Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

• Status: Completed
• Trial end date: 2000-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase I trial to study the effectiveness of topotecan and radiation therapy in treating patients who have solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Topotecan

Criteria

DISEASE CHARACTERISTICS:

• Microscopically confirmed solid tumor or lymphoma not potentially curable by conventional surgery or radiotherapy

• Previously unirradiated disease scheduled to receive thoracic irradiation of up to 60 Gy, including pulmonary and esophageal tumors

• No metastatic disease more effectively treated by systemic chemotherapy

• No history of brain metastases

PATIENT CHARACTERISTICS:

• Age: 18 and over

• Performance status: ECOG 0 or 1

• WBC at least 4,000

• ANC at least 1,500

• Platelets at least 100,000

• Bilirubin no greater than 1.5 mg/dL

• Creatinine no greater than 1.5 mg/dL

• Calcium no greater than 11.0 mg/dL

• No pregnant or nursing women

• Pregnancy test required, as appropriate

• Effective contraception required of fertile patient

PRIOR CONCURRENT THERAPY:

• At least 4 weeks since chemotherapy (6 weeks since nitrosoureas and mitomycin) and recovered

• At least 4 weeks since radiotherapy and recovered